<DOC>
	<DOCNO>NCT02734771</DOCNO>
	<brief_summary>This study incorporate brentuximab vedotin dose attenuate rituximab , cyclophosphamide , doxorubicin , prednisone ( R-CHP ) initial therapy elderly patient DLBCL . Vincristine omit standard R-CHOP regimen give overlap toxicity brentuximab vedotin .</brief_summary>
	<brief_title>A Study Brentuximab Vedotin , Rituximab , Dose Attenuated CHP Elderly Patients With Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>This multicenter , single-arm pilot study incorporate brentuximab vedotin dose attenuate rituximab , cyclophosphamide , doxorubicin , prednisone ( R-CHP ) initial therapy elderly patient DLBCL . Vincristine omit standard R-CHOP regimen give overlap toxicity brentuximab vedotin . CD30 positivity determine enrollment patient enrol CD30 positive negative group equal number . Additionally , Comprehensive Geriatric Assessment ( CGA ) perform patient , use guide treatment decision .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Voluntary write informed consent performance studyspecific procedure part routine medical care , understand consent may withdraw subject time without prejudice future medical care . Subjects must able understand willing sign write informed consent form . Men woman age great equal 75 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 03 Histologicallyconfirmed DLBCL World Health Organization classification site hematopathologist Histologic transformation ( HT ) include study . This must confirm biopsy . Patients HT must receive anthracyclinecontaining regimen past . Composite lymphoma contain indolent large cell feature include Has receive prior therapy DLBCL HT exception course prednisone less equal 7 day give lymphoma related symptom ; prior therapy follicular lymphoma accept , prior anthracyclinecontaining therapy . Carriers hepatitis B virus closely monitor clinical laboratory sign active hepatitis B virus infection sign hepatitis throughout study participation . Total bilirubin must less 1.5 time upper limit normal ( ULN ) unless elevation know due Gilbert syndrome . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) must less 3 time upper limit normal range . AST ALT may elevate 5 time ULN elevation reasonably ascribe presence DLBCL liver . Patient platelet count ≤50,000/mm3 within 14 day enrollment . Patient absolute neutrophil count &lt; 1,000/mm3 within 14 day enrollment . Patient calculate measured creatinine clearance &lt; 30 mL/minute within 14 day enrollment . Patient receive peritoneal dialysis hemodialysis Patient ≥Grade 2 peripheral neuropathy within 14 day enrollment . Serious medical psychiatric illness likely interfere participation clinical study . New York Heart Association class III heart failure ejection fraction le 30 % echocardiogram Multi Gated Acquisition Scan ( MUGA ) Patient receive investigational drug 14 day enrollment Prior exposure anthracycline Patient concomitant active malignancy treat physician PI feel may interfere ability measure primary secondary outcome Patients history curative , surgically treat basal squamous cell carcinoma stage 1 melanoma skin situ carcinoma cervix eligible . Patients malignancy treat surgery alone curative intent also exclude , unless malignancy document remission without treatment ≥ 3 year prior enrollment . Patient known HIV positive ( test result require enrollment ) . History solid organ transplantation , posttransplant lymphoproliferative disorder Patient history allogeneic stem cell transplantation . History , clinically apparent central nervous system ( CNS ) lymphoma Any clinically significant abnormality screen blood chemistry , hematology , urinalysis result , judgment investigator , would impede adequate evaluation adverse event and/or response treatment , require aggressive intervention</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DLBCL</keyword>
</DOC>